Compare Crispr Therapeutics AG (CRSP) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Crispr Therapeutics AG trades at $53.69 (market cap $4.88B), while iShares 0 3 Month Treasury Bond ETF trades at $100.52 (market cap $114.40B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 23.4× Crispr Therapeutics AG's market cap, and iShares 0 3 Month Treasury Bond ETF is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and iShares 0 3 Month Treasury Bond ETF for 50 Days on average.
| CRSP | SGOV | |
|---|---|---|
Market Cap | $4.88B | $114.40B |
Volume | 2,861,747 | 18,879,081 |
Sector | Health | Fixed Income |
52-Week High | $74.92 | $100.72 |
52-Week Low | $44.34 | $100.28 |
Typical Hold Time | 77 Days | 50 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% with bearish technical signals. The company shows negative profitability metrics including -$581.6M net income and -4,101.26% net margin for 2025, though revenue is expected to grow from $0 to $11M in 2026. Recent news highlights upcoming clinical data presentations and CASGEVY's commercial potential, with analyst consensus leaning bullish despite fundamental challenges.
The outlook remains speculative with significant cash burn but promising pipeline catalysts. Investment opportunity lies in gene-editing breakthroughs and CASGEVY adoption, while risks include sustained losses, clinical trial outcomes, and competitive pressure. Wall Street maintains a $67.83 price target, suggesting 30% upside if execution improves.
SGOV trades at $100.51 with minimal daily movement (+0.04%), reflecting its stable Treasury bond ETF nature. Technical indicators show bearish momentum with oversold RSI readings, while fundamental data remains limited for this short-term Treasury fund. Recent institutional selling by Envestnet Asset Management indicates some professional caution, though the fund continues regular dividend distributions.
The outlook remains stable given SGOV's short-term Treasury focus, though rising bond yields present both opportunity and risk. Investors benefit from monthly dividends but face interest rate sensitivity. Current technical weakness suggests potential near-term pressure despite the fund's defensive characteristics in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
